Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SynoviG3 is a veterinary dietary supplement formulated as flavored soft chews or chewable tablets for dogs to support hip and joint health, flexibility, and normal muscle function. The product combines glucosamine hydrochloride to support cartilage matrix and joint lubrication, methylsulfonylmethane (MSM) as a sulfur donor with anti‑inflammatory and connective‑tissue support properties, creatine monohydrate to aid muscle strength, and green‑lipped mussel and omega‑3 fatty acids to provide additional chondroprotective and anti‑inflammatory effects.[1][2][3][5] It is marketed primarily for active dogs or those with stiffness after activity to help maintain healthy joints and cartilage, and is sold through veterinarians and retail channels as an over‑the‑counter companion‑animal joint supplement.[1][2][3][5][6][7]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SynoviG3.